BioCentury | Sep 5, 2020
Translation in Brief

Matt Disney’s microRNA-targeting angiogenesis compound; Arrakis’ platform to find compounds’ RNA targets; dual target CAR Ts for HIV and more

...identify drug targetsIn an ACS Chemical Biology paper, Arrakis Therapeutics Inc....
...MicroRNA-377VEGF-A – Vascular endothelial growth factor A Danielle Golovin Arrakis Therapeutics Inc. The...
BioCentury | May 23, 2020
Politics, Policy & Law

SURVEY: As companies return to workplace, testing will take a back seat to multiple safety measures

...with 80% of companies anticipating using virtual technologies. Companies, such as Roche (SIX:ROG; OTCQX:RHHBY) and Arrakis Therapeutics Inc....
BioCentury | May 9, 2020
Deals

The Roche-Arrakis deal in their own words

...what the partners didn’t let get in the way. The negotiations landed RNA-targeting therapeutics developer Arrakis Therapeutics Inc....
...things that you need to really create value in our business. C. Simone Fishburn, Editor in Chief Roche Arrakis Therapeutics Inc. podcast...
BioCentury | May 6, 2020
Deals

Consummating a deal under lockdown: Roche and Arrakis in a BioCentury podcast

...This Week -- Special Report PODCAST . Gilman discusses why, after spurning inbound interest in Arrakis Therapeutics Inc....
...be a “partnership of equals” to succeed (see “Arrakis Taps Roche” ). BC Staff Jeff Cranmer, Executive Editor Arrakis Therapeutics Inc. Roche podcast covid-19 Michael...
BioCentury | Apr 18, 2020
Product Development

Investors are still waiting for the other shoe to drop on a slowdown in deal flow

...with the previous four quarters. Source: BioCentury's BCIQ database Lauren Martz, Senior Editor Sofinnova Partners Novartis AG Tango Therapeutics Inc. Arrakis Therapeutics Inc. COVID-19...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...Rgenta, most are not seeking to manipulate RNA-RBP interactions. Expansion Therapeutics Inc., Ribometrix Inc. and Arrakis Therapeutics Inc....
BioCentury | Apr 8, 2020
Deals

RNA-targeting small molecule play Arrakis taps Roche as first pharma partner

...while allowing it to remain an independent company with an eye on an eventual listing. Arrakis Therapeutics Inc....
...structure, however, and that talks were fairly advanced prior to the outbreak’s effects. Paul Bonanos, Associate Editor Arrakis Therapeutics Inc. Roche...
BioCentury | Jan 21, 2020
Tools & Techniques

Disney lab uncovers another RNA-binding small molecule for triple-negative breast cancer

...company’s board, and Expansion could not be reached for comment. At least two other companies, Arrakis Therapeutics Inc....
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...addition to Nuvation, they include asset-focused company IFM Therapeutics LLC and RNA-targeting small molecule play Arrakis Therapeutics Inc....
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...La Sablière, head of business development, and Laurent Van Lerberghe, head of strategy. RNA-targeting company Arrakis Therapeutics Inc....
...she also served as CEO from 2010-18. Elizabeth S. Eaton, Staff Writer Sanofi MorphoSys AG Kymera Therapeutics Inc. Kronos Bio Inc. Arrakis Therapeutics Inc. Coda...
Items per page:
1 - 10 of 45
BioCentury | Sep 5, 2020
Translation in Brief

Matt Disney’s microRNA-targeting angiogenesis compound; Arrakis’ platform to find compounds’ RNA targets; dual target CAR Ts for HIV and more

...identify drug targetsIn an ACS Chemical Biology paper, Arrakis Therapeutics Inc....
...MicroRNA-377VEGF-A – Vascular endothelial growth factor A Danielle Golovin Arrakis Therapeutics Inc. The...
BioCentury | May 23, 2020
Politics, Policy & Law

SURVEY: As companies return to workplace, testing will take a back seat to multiple safety measures

...with 80% of companies anticipating using virtual technologies. Companies, such as Roche (SIX:ROG; OTCQX:RHHBY) and Arrakis Therapeutics Inc....
BioCentury | May 9, 2020
Deals

The Roche-Arrakis deal in their own words

...what the partners didn’t let get in the way. The negotiations landed RNA-targeting therapeutics developer Arrakis Therapeutics Inc....
...things that you need to really create value in our business. C. Simone Fishburn, Editor in Chief Roche Arrakis Therapeutics Inc. podcast...
BioCentury | May 6, 2020
Deals

Consummating a deal under lockdown: Roche and Arrakis in a BioCentury podcast

...This Week -- Special Report PODCAST . Gilman discusses why, after spurning inbound interest in Arrakis Therapeutics Inc....
...be a “partnership of equals” to succeed (see “Arrakis Taps Roche” ). BC Staff Jeff Cranmer, Executive Editor Arrakis Therapeutics Inc. Roche podcast covid-19 Michael...
BioCentury | Apr 18, 2020
Product Development

Investors are still waiting for the other shoe to drop on a slowdown in deal flow

...with the previous four quarters. Source: BioCentury's BCIQ database Lauren Martz, Senior Editor Sofinnova Partners Novartis AG Tango Therapeutics Inc. Arrakis Therapeutics Inc. COVID-19...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...Rgenta, most are not seeking to manipulate RNA-RBP interactions. Expansion Therapeutics Inc., Ribometrix Inc. and Arrakis Therapeutics Inc....
BioCentury | Apr 8, 2020
Deals

RNA-targeting small molecule play Arrakis taps Roche as first pharma partner

...while allowing it to remain an independent company with an eye on an eventual listing. Arrakis Therapeutics Inc....
...structure, however, and that talks were fairly advanced prior to the outbreak’s effects. Paul Bonanos, Associate Editor Arrakis Therapeutics Inc. Roche...
BioCentury | Jan 21, 2020
Tools & Techniques

Disney lab uncovers another RNA-binding small molecule for triple-negative breast cancer

...company’s board, and Expansion could not be reached for comment. At least two other companies, Arrakis Therapeutics Inc....
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...addition to Nuvation, they include asset-focused company IFM Therapeutics LLC and RNA-targeting small molecule play Arrakis Therapeutics Inc....
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...La Sablière, head of business development, and Laurent Van Lerberghe, head of strategy. RNA-targeting company Arrakis Therapeutics Inc....
...she also served as CEO from 2010-18. Elizabeth S. Eaton, Staff Writer Sanofi MorphoSys AG Kymera Therapeutics Inc. Kronos Bio Inc. Arrakis Therapeutics Inc. Coda...
Items per page:
1 - 10 of 45